Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: Current state of the art and future directions

Minerva Endocrinologica

Volumn 37, Issue 4, 2012, Pages 335-356

  Dadu, R ^a,b   Cabanillas, M E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Carcinoma, papillary; Drug therapy; Protein tyrosine kinases; Thyroid neoplasms

Indexed keywords

ANTITHYROID AGENT; AXITINIB; BISPHOSPHONIC ACID DERIVATIVE; CABOZANTINIB; DABRAFENIB; DENOSUMAB; EVEROLIMUS; EXEMESTANE; FLUORODEOXYGLUCOSE F 18; GEFITINIB; LENVATINIB; LIVER ENZYME; MOTESANIB; PAZOPANIB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RADIOACTIVE IODINE; SELUMETINIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THYROGLOBULIN; THYROGLOBULIN ANTIBODY; THYROTROPIN; TIPIFARNIB; TRIACYLGLYCEROL LIPASE; UNINDEXED DRUG; VANDETANIB; VEMURAFENIB; ZOLEDRONIC ACID;

ABDOMINAL PAIN; ALOPECIA; ANOREXIA; ARTERIAL THROMBOEMBOLISM; ARTERY THROMBOSIS; ARTHRALGIA; ARTIFICIAL EMBOLISM; ASTHENIA; BLEEDING; BONE METASTASIS; BONE PAIN; BONE SCINTISCANNING; BRAIN HEMORRHAGE; BRAIN METASTASIS; BRAIN SURGERY; BREAST CANCER; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER REGRESSION; CANCER SURVIVAL; CARCINOGENESIS; CLASSIFICATION ALGORITHM; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONGESTIVE HEART FAILURE; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DIFFERENTIATED THYROID CANCER; DIGESTIVE SYSTEM PERFORATION; DISTANT METASTASIS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPHONIA; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEVER; FISTULA; FOOT PAIN; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HAIR DISEASE; HAND FOOT SYNDROME; HAND PAIN; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE TACHYCARDIA; HEMATURIA; HUMAN; HYPERTENSION; HYPONATREMIA; HYPOPIGMENTATION; HYPOTHYROIDISM; IC 50; KIDNEY CARCINOMA; LEUKOPENIA; LIVER METASTASIS; LIVER TOXICITY; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MELANOMA; METASTASIS RESECTION; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL CHEST PAIN; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREATIC NEUROENDOCRINE TUMOR; PATIENT MONITORING; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY DISORDER; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROCESS OPTIMIZATION; PROGRESSION FREE SURVIVAL; PROTEINURIA; PROTO ONCOGENE; PRURITUS; QT PROLONGATION; RADIOISOTOPE THERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN EXFOLIATION; SKIN MANIFESTATION; SKIN PAPILLOMA; SOFT TISSUE SARCOMA; SQUAMOUS CELL CARCINOMA; STEREOTACTIC RADIOSURGERY; STOMATITIS; SUDDEN DEATH; SYSTEMIC THERAPY; THYROID PAPILLARY CARCINOMA; TORSADE DES POINTES; TREATMENT RESPONSE; UVEITIS; VEIN THROMBOSIS; VOMITING; WEIGHT REDUCTION; WHOLE BODY SCINTISCANNING; WOUND DEHISCENCE; WOUND HEALING IMPAIRMENT;

ADENOCARCINOMA, FOLLICULAR; ADENOMA, OXYPHILIC; ALGORITHMS; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BRAIN NEOPLASMS; CARCINOMA, PAPILLARY; CLINICAL TRIALS, PHASE II AS TOPIC; COMBINED MODALITY THERAPY; DIAGNOSTIC IMAGING; DISEASE PROGRESSION; DOXORUBICIN; FORECASTING; HUMANS; IODINE RADIOISOTOPES; LIVER NEOPLASMS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; RADIATION TOLERANCE; RADIOPHARMACEUTICALS; THYROID NEOPLASMS; THYROIDECTOMY; THYROTROPIN;

EID: 84875305916     PISSN: 03911977     EISSN: 18271634     Source Type: Journal    
DOI: None     Document Type: Review

References (99)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006;91:2892-9. (Pubitemid 44271732)
3. Ringel MD. Metastatic dormancy and progression in thyroid cancer: targeting cells in the metastatic frontier. Thyroid 2011;21(5):487-92.
4. Deandreis D, Al Ghuzlan A, Leboulleux S, Lacroix L, Garsi JP, Talbot M et al. Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome? Endocr Relat Cancer 2011;18(1):159-69.
5. Robbins RJ, Wan Q, Grewal RK, Reibke R, Gonen M, Strauss HW et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006,91(2):498-505. (Pubitemid 43236915)
6. Leboulleux S, El Bez I, Borget I, Elleuch M, Deandreis D, Al Ghuzlan A et al. Post-Radioiodine Treatment Whole Body Scan in the Era of Fluorodesoxyglucose Positron Emission Tomography for Differentiated Thyroid Carcinoma with elevated serum thyroglobulin levels. Thyroid 2012.
7. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
8. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
9. Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL et al. We should desist using RECIST, at least in GIST. J Clin Oncol 2007;25:1760-4. (Pubitemid 46797958)
10. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 2009;50(Suppl 1):122S-50S.
11. Eustatia-Rutten CF, Corssmit EP, Biermasz NR, Pereira AM, Romijn JA, Smit JW. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab 2006;91):313-9.
12. Dinneen SF, Valimaki MJ, Bergstralh EJ, Goellner JR, Gorman CA, Hay ID. Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades. J Clin Endocrinol Metab 1995;80:2041-5.
13. Schwartz DL, Lobo MJ, Ang KK, Morrison WH, Rosenthal DI, Ahamad A et al. Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatment. Int J Radiat Oncol Biol Phys 2009;74:1083-91.
14. Tuttle RM, Rondeau G, Lee NY. A risk-adapted approach to the use of radioactive iodine and external beam radiation in the treatment of well-differentiated thyroid cancer. Cancer Control 2011;18:89-95.
15. Lee N, Tuttle M. The role of external beam radiotherapy in the treatment of papillary thyroid cancer. Endocr Relat Cancer 2006;13:971-7. (Pubitemid 46212559)
16. Brierley JD, Tsang RW. External beam radiation therapy for thyroid cancer. Endocrinol Metab Clin North Am 2008;37:497-509, xi. (Pubitemid 351698085)
17. Strasser JF, Raben A, Koprowski C. The role of radiation therapy in the management of thyroid cancer. Surg Oncol Clin N Am 2008;17:219-32, x.
18. Spigel DR, Hainsworth JD, Yardley DA, Raefsky E, Patton J, Peacock N et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol 2010;28:43-8.
19. Muresan MM, Olivier P, Leclere J, Sirveaux F, Brunaud L, Klein M et al. Bone metastases from differentiated thyroid carcinoma. Endocr Relat Cancer 2008;15:37-49. (Pubitemid 351449726)
20. Pittas AG, Adler M, Fazzari M, Tickoo S, Rosai J, Larson SM et al. Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients. Thyroid 2000;10:261-8.
21. Orita Y, Sugitani I, Matsuura M, Ushijima M, Tsukahara K, Fujimoto Y et al. Prognostic factors and the therapeutic strategy for patients with bone metastasis from differentiated thyroid carcinoma. Surgery 2010;147:424-31.
22. Sugitani I, Fujimoto Y, Yamamoto N. Papillary thyroid carcinoma with distant metastases: survival predictors and the importance of local control. Surgery 2008;143:35-42. (Pubitemid 350266026)
23. Farooki A, Leung V, Tala H, Tuttle RM. Skeletal-Related Events due to Bone Metastases from Differentiated Thyroid Cancer. J Clin Endocrinol Metab 2012,97:2433-9.
24. Qiu ZL, Song HJ, Xu YH, Luo QY. Efficacy and survival analysis of 131I therapy for bone metastases from differentiated thyroid cancer. J Clin Endocrinol Metab 2011;96:3078-86.
25. Orita Y, Sugitani I, Toda K, Manabe J, Fujimoto Y. Zoledronic acid in the treatment of bone metastases from differentiated thyroid carcinoma. Thyroid 2011;21:31-5.
26. Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009;27:1564-71.
27. Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 2007;25:4431-7. (Pubitemid 350013849)
28. Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29:1125-32.
29. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, doubleblind study. J Clin Oncol 2010;28:5132-9.
30. McWilliams RR, Giannini C, Hay ID, Atkinson JL, Stafford SL, Buckner JC. Management of brain metastases from thyroid carcinoma: a study of 16 pathologically confirmed cases over 25 years. Cancer 2003;98:356-62. (Pubitemid 36828462)
31. Chiu AC, Delpassand ES, Sherman SI. Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab 1997;82:3637-42. (Pubitemid 27509349)
32. Bernad DM, Sperduto PW, Souhami L, Jensen AW, Roberge D. Stereotactic radiosurgery in the management of brain metastases from primary thyroid cancers. J Neurooncol 2010;98:249-52.
33. Kim IY, Kondziolka D, Niranjan A, Flickinger JC, Lunsford LD. Gamma knife radiosurgery for metastatic brain tumors from thyroid cancer. J Neurooncol 2009;93:355-9.
34. Salvatori M, Perotti G, Rufini V, Maussier ML, Summaria V, Fadda G et al. Solitary liver metastasis from Hurthle cell thyroid cancer: a case report and review of the literature. J Endocrinol Invest 2004;27:52-6. (Pubitemid 38324720)
35. Fromigue J, De Baere T, Baudin E, Dromain C, Leboulleux S, Schlumberger M. Chemoembolization for liver metastases from medullary thyroid carcinoma. J Clin Endocrinol Metab 2006;91:2496-9. (Pubitemid 44024606)
36. Wertenbroek MW, Links TP, Prins TR, Plukker JT, van der Jagt EJ, de Jong KP. Radiofrequency ablation of hepatic metastases from thyroid carcinoma. Thyroid 2008;18:1105-10.
37. Berber E, Ari E, Herceg N, Siperstein A. Laparoscopic radiofrequency thermal ablation for unusual hepatic tumors: operative indications and outcomes. Surg Endosc 2005;19:1613-7. (Pubitemid 41719530)
38. Andreou A, Brouquet A, Bharathy KG, Perrier ND, Abdalla EK, Curley SA et al. Liver resection for liver metastases from nondigestive endocrine cancer: extrahepatic disease burden defines outcome. Surgery 2012;151:851-9.
39. Schlumberger M, Sherman SI. Clinical trials for progressive differentiated thyroid cancer: patient selection, study design, and recent advances. Thyroid 2009;19:1393-400.
40. Deandreis D, Al Ghuzlan A, Leboulleux S, Lacroix L, Garsi JP, Talbot M et al. Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome? Endocrinerelated cancer 2011;18:159-69.
41. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-214.
42. Tuttle RM, Ball DW, Byrd D, Dilawari RA, Doherty GM, Duh QY et al. Thyroid carcinoma. J Natl Compr Canc Netw 2010;8:1228-74.
43. Henderson YC, Shellenberger TD, Williams MD, ElNaggar AK, Fredrick MJ, Cieply KM et al. High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma. Clin Cancer Res 2009;15:485-91.
44. Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 2008;93:3943-9.
45. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005;12:245-62. (Pubitemid 40896444)
46. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005,90:6373-9. (Pubitemid 41759286)
47. Ugolini C, Giannini R, Lupi C, Salvatore G, Miccoli P, Proietti A et al. Presence of BRAF V600E in very early stages of papillary thyroid carcinoma. Thyroid 2007;17:381-8. (Pubitemid 46878840)
48. Kim TY, Kim WB, Rhee YS, Song JY, Kim JM, Gong G et al. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2006;65:364-8.
49. Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, Pardo J et al. ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol 2003;21:3226-35. (Pubitemid 46606254)
50. Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW, 2nd, Tallini G et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 2003;88:2318-26. (Pubitemid 36549913)
51. Riesco-Eizaguirre G, Gutierrez-Martinez P, Garcia-Cabezas MA, Nistal M, Santisteban P. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. Endocr Relat Cancer 2006;13:257-69.
52. Howell GM, Carty SE, Armstrong MJ, Lebeau SO, Hodak SP, Coyne C et al. Both BRAF V600E mutation and older age (≥65 years) are associated with recurrent papillary thyroid cancer. Ann Surg Oncol 2011;18:3566-71.
53. Ricarte-Filho J, Ganly I, Rivera M, Katabi N, Fu W, Shaha A et al. Papillary thyroid carcinomas with cervical lymph node metastases can be stratified into clinically relevant prognostic categories using oncogenic BRAF, the number of nodal metastases, and extra-nodal extension. Thyroid 2012;22:575-84.
54. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000;6:389-95. (Pubitemid 30208155)
55. Lennard CM, Patel A, Wilson J, Reinhardt B, Tuman C, Fenton C et al. Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. Surgery 2001;129:552-8. (Pubitemid 32374986)
56. Klein M, Vignaud JM, Hennequin V, Toussaint B, Bresler L, Plenat F et al. Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J Clin Endocrinol Metab 2001;86:656-8. (Pubitemid 32207476)
57. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008;26:4714-9.
58. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009;27:1675-84.
59. Hoftijzer H, Heemstra KA, Morreau H, Stokkel MP, Corssmit EP, Gelderblom H et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 2009;161:923-31.
60. Schneider T, Abdulrahman R, Corssmit EP, Morreau H, Smit JW, Kapiteijn E. Long term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial. Eur J Endocrinol 2012;167:643-50.
61. Ahmed M, Barbachano Y, Riddell A, Hickey J, Newbold KL, Viros A et al. Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. Eur J Endocrinol 2011;165:315-22.
62. Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, Hernandez M et al. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J Clin Endocrinol Metab 2010;95:2588-95.
63. Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 2011;16:5260-8.
64. Personal communication with Renato Martins ed, 2010.
65. Ravaud A, De la Fouchardiere C, Courbon F, Asselineau J, Klein M, Nicoli-Sire P et al. Sunitinib in patients with refractory advanced thyroid cancer: the THYSU phase II trial. J Clin Oncol 2008;26(Suppl):abstr 6058.
66. Cohen E, Needles B, Cullen K, Wong S, Wade J, Ivy S et al. Phase 2 study of sunitinib in refractory thyroid cancer. J Clin Oncol 2008;26(Suppl): abstr 6025.
67. Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 2011;11:962-72.
68. Wells SA, Jr., Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012;30:134-41.
69. Leboulleux S, Bastholt L, Krause T, de la Fouchardiere C, Tennvall J, Awada A et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol 2012;13:897-905.
70. Flaherty ICT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19.
71. Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005;23:5474-83.
72. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008;26:4708-13.
73. Pennell NA, Daniels GH, Haddad RI, Ross DS, Evans T, Wirth LJ et al. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid 2008;18:317-23. (Pubitemid 351415790)
74. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 2008;359:31-42. (Pubitemid 351931094)
75. Bass MB, Sherman SI, Schlumberger MJ, Davis MT, Kivman L, Khoo HM et al. Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer. J Clin Endocrinol Metab 2010;95:5018-27.
76. Hayes DN, Lucas AS, Tanvetyanon T, Krzyzanowska MK, Chung CH, Murphy BA et al. Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res 2012;18:2056-65.
77. Cabanillas ME, Brose MS, Lee Y, Miles D, Sherman SI. Antitumor activity of cabozantinib (XL184) in a cohort of patients (pts) with differentiated thyroid cancer (DTC). J Clin Oncol 2012;30(Suppl):abstr 5547.
78. Sherman SI, Jarzab B, Cabanillas ME, Licitra L, Pacini F, Martins R et al. A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). J Clin Oncol 2011;29(Suppl):abstr 5503.
79. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012;379:1893-901.
80. Hong DS, Cabanillas ME, Wheler J, Naing A, Tsimberidou AM, Ye L et al. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J Clin Endocrinol Metab 2011;96:997-1005.
81. Sherman E, Ho AL, Fury M, Baxi SS, Haque S, Korte SH et al. A phase II study of temsirolimus/sorafenib in patients with radioactive iodine (RAI)-refractory thyroid carcinoma. J Clin Oncol 2012;30(Suppl):abstr 5514.
82. Zimmermann K, Schmittel A, Steiner U, Asemissen AM, Knoedler M, Thiel E et al. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology 2009;76:350-4.
83. Griming T, Tiepolt C, Zophel K, Bredow J, Kropp J, Franke WG. Retinoic acid for redifferentiation of thyroid cancer - does it hold its promise? Eur J Endocrinol 2003;148:395-402. (Pubitemid 36527410)
84. Liu YY, Stokkel MP, Pereira AM, Corssmit EP, Morreau HA, Romijn JA et al. Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma. Eur J Endocrinol 2006;154:525-31.
85. Su YB, Tuttle RM, Fury M, Ghossein R, Singh B, Herman K et al. A phase II study of single agent depsipeptide (DEP) in patients (pts) with radioactive iodine (RAI)-refractory, metastatic, thyroid carcinoma: Preliminary toxicity and efficacy experience. J Clin Oncol 2006;24(Suppl):abstr 5554.
86. Kebebew E, Peng M, Reiff E, Treseler P, Woeber KA, Clark OH et al. A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer. Surgery 2006;140:960-6; discussion 66-7.
87. Chakravarty D, Santos E, Ryder M, Knauf JA, Liao XH, West BL et al. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest 2011;121):4700-11.
88. Ho L, Leboeuf R, Grewal RK, Sherman EJ, Deandreis D, Pentlow K et al. Reacquisition of RAI uptake in RAI-refractory metastatic thyroid cancers by pretreatment with the MEK inhibitor selumetinib. J Clin Oncol 2012;30(Suppl):abstr 5509.
89. French JD, Kotnis GR, Said S, Raeburn CD, McIntyre RC, Jr., Klopper JP et al. Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer. J Clin Endocrinol Metab 2012;97:E934-43.
90. French JD, Weber ZJ, Fretwell DL, Said S, Klopper JP, Haugen BR. Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer. J Clin Endocrinol Metab 2010;95:2325-33.
91. Cabanillas ME, Hu MI, Durand JB, Busaidy NL. Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer. J Thyroid Res 2011;2011:985780.
92. Busaidy NL, Cabanillas ME. Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease. J Thyroid Res 2012;2012:618985.
93. Sherman SI. Molecularly targeted therapies for thyroid cancers. Endocr Pract 2009;15:605-11.
94. Busaidy NL, Cabanillas ME. Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease. J Thyroid Res 2012;2012:618985.
95. Sonpavde G, Hutson TE, Sternberg CN. Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. Expert Opin Investig Drugs 2008;17:253-61. (Pubitemid 351578205)
96. Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 2008;14:5459-65.
97. Matsui J, Yamamoto Y, Funahashi Y, Tsuruoka A, Watanabe T, Wakabayashi T et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 2008;122:664-71. (Pubitemid 350308963)
98. Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011;10:2298-308.
99. Yeh TC, Marsh V, Bernat BA, Ballard J, Colwell H, Evans RJ et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res 2007;13:1576-83. (Pubitemid 46450450)